文献速递乳腺MR

乳腺癌患者合成扩散加权MRI与常规扩散加权MRI对比的可行性研究

Feasibility Study of Synthetic Diffusion-Weighted MRI in Patients with Breast Cancer in Comparison with Conventional Diffusion-Weighted MRI.
PubMed 文献 · Korean J Radiol · 2020-01-01

本研究纳入50例乳腺癌患者,比较常规扩散加权成像(cDWI)与合成扩散加权成像(sDWI)在不同b值下的图像质量和定量测量。结果显示sDWI1500在病灶清晰度和癌-实质对比比方面优于cDWI1500,而cDWI1500在正常腺体抑制和整体图像质量方面更优,两者癌检出率无显著差异(均为90.0%)。作者认为sDWI1500在临床实践中用于评估乳腺癌是可行的。

要点

  • sDWI1500的病灶清晰度评分高于cDWI1500(3.52±0.92 vs. 3.39±0.90,p<0.05)。
  • cDWI1500的正常腺体抑制和整体图像质量评分均高于sDWI1500(p<0.05)。
  • 两种序列的癌检出率无显著差异,均为90.0%。

关键影像表现/征象

  • 所有定性分析参数、癌-实质对比比和癌检出率均随b值增加而升高,无论合成或常规成像(p<0.001)。
  • sDWI1500的病灶清晰度优于cDWI1500(3.52±0.92 vs. 3.39±0.90,p<0.05)。
  • cDWI1500的正常腺体抑制和整体图像质量均优于sDWI1500(分别为3.66±0.78和3.73±0.62 vs. 3.32±0.90和3.35±0.81,p<0.05)。
  • sDWI1500的癌-实质对比比大于cDWI1500(0.63±0.17 vs. 0.55±0.18,p<0.001)。

诊断标准与关键数值

  • 定性分析采用4分Likert量表评估正常腺体抑制、整体图像质量和病灶清晰度。
  • 癌检出率在cDWI1500和sDWI1500之间无显著差异,均为90.0%。

临床应用与阅片要点

  • sDWI1500可考虑用于评估乳腺癌,其病灶清晰度和癌-实质对比比优于cDWI1500,癌检出率相当。
  • cDWI1500在正常腺体抑制和整体图像质量方面优于sDWI1500,阅片时需注意序列间的差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the clinical feasibility of synthetic diffusion-weighted imaging (sDWI) at different b-values in patients with breast cancer by assessing the diagnostic image quality and the quantitative measurements compared with conventional diffusion-weighted imaging (cDWI).

MATERIALS AND METHODS: Fifty patients with breast cancer were assessed using cDWI at b-values of 800 and 1500 s/mm² (cDWI800 and cDWI1500) and sDWI at b-values of 1000 and 1500 s/mm² (sDWI1000 and sDWI1500). Qualitative analysis (normal glandular tissue suppression, overall image quality, and lesion conspicuity) was performed using a 4-point Likert-scale for all DWI sets and the cancer detection rate (CDR) was calculated. We also evaluated cancer-to-parenchyma contrast ratios for each DWI set in 45 patients with the lesion identified on any of the DWI sets. Statistical comparisons were performed using Friedman test, one-way analysis of variance, and Cochran's Q test.

RESULTS: All parameters of qualitative analysis, cancer-to-parenchyma contrast ratios, and CDR increased with increasing b-values, regardless of the type of imaging (synthetic or conventional) (p < 0.001). Additionally, sDWI1500 provided better lesion conspicuity than cDWI1500 (3.52 ± 0.92 vs. 3.39 ± 0.90, p < 0.05). Although cDWI1500 showed better normal glandular tissue suppression and overall image quality than sDWI1500 (3.66 ± 0.78 and 3.73 ± 0.62 vs. 3.32 ± 0.90 and 3.35 ± 0.81, respectively; p < 0.05), there was no significant difference in their CDR (90.0%). Cancer-to-parenchyma contrast ratios were greater in sDWI1500 than in cDWI1500 (0.63 ± 0.17 vs. 0.55 ± 0.18, p < 0.001).

CONCLUSION: sDWI1500 can be feasible for evaluating breast cancers in clinical practice. It provides higher tumor conspicuity, better cancer-to-parenchyma contrast ratio, and comparable CDR when compared with cDWI1500.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Choi BH, Baek HJ, Ha JY, et al. Feasibility Study of Synthetic Diffusion-Weighted MRI in Patients with Breast Cancer in Comparison with Conventional Diffusion-Weighted MRI. Korean J Radiol. 2020. PMID: 32691539. doi:10.3348/kjr.2019.0568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。